USPTO serial 76635438
ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 23, 2007
- Examiner
- CLARK, ROBERT C
- Law office
- GENERIC WEB UPDATE
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
SALT LAKE CITY, UT, US
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lester K. Essig
Lester K. Essig Ray Quinney & Nebeker36 South State StreetSuite 1400Salt Lake City, UT 84111Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Clinical laboratory services, reference laboratory services, diagnostic laboratory services, medical laboratory services, and providing medical laboratory information online over the global communications network, all in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, inununofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; clinical laboratory services, reference laboratory services, dissection laboratory services, diagnostic laboratory services, medical laboratory services, veterinary laboratory services, and medical and scientific research, namely, collecting, processing, treating, freezing, staining, dissecting, analyzing, screening, testing, typing and storing of biological substances and human and animal tissue, blood, blood components, cells, stems cells, abnormal cells, chromosomes and nucleic acid; development, improvement, evaluation, analysis and application of clinical laboratory tests and diagnostics in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; and medical research in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care | ACTIVE | Mar 1, 2000 |
| 044 | Medical testing services in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; and providing medical information online over a global communications network in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopatho logy, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care | ACTIVE | Mar 1, 2000 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Associated Regional and University Pathologists, Inc.
- Other trademarks owned by ARUP LABORATORIES, INC.
- Other trademarks owned by Associated Regional and University Pathologists, Inc.
- Other trademarks owned by Associated Regional and University Pathologists, Inc.
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 28, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 28, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 18, 2017 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - MAILED | — |
| Nov 18, 2017 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Nov 18, 2017 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Nov 18, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 23, 2017 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Feb 5, 2014 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED | — |
| Feb 4, 2014 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Feb 4, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 23, 2014 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Jan 23, 2014 | PAPER RECEIVED | — | |
| Mar 20, 2013 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 23, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 7, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 18, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 5, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 22, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 7, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jun 7, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 7, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 16, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| May 16, 2007 | ALIE | ASSIGNED TO LIE | — |
| Apr 25, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2007 | PAPER RECEIVED | — | |
| Nov 3, 2006 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 3, 2006 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 12, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 25, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 25, 2006 | PAPER RECEIVED | — | |
| Mar 24, 2006 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 8, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 20, 2005 | NWAP | NEW APPLICATION ENTERED | — |